Cancers, Vol. 11, Pages 1601: Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer
Cancers, Vol. 11, Pages 1601: Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer Cancers doi: 10.3390/cancers11101601 Authors: Alice Blondel Amine Benberghout Rémy Pedeux Charles Ricordel Non-small cell lung cancer (NSCLC) has been the leading cause of cancer-related death worldwide, over the last few decades. Survival remains extremely poor in the metastatic setting and, consequently, innovative therapeutic strategies are urgently needed. Inhibitor of Growth Gene 2 (ING2) is a core component of the mSin3A/Histone deacetylases complex (HDAC), which controls the chromatin acetylation status and modulates gene transcription. This gene has been characterized as a tumor suppressor gene and its status in cancer has been scarcely explored. In this review, we focused on ING2 and other mSin3A/HDAC member statuses in NSCLC. Taking advantage of existing public databases and known pharmacological properties of HDAC inhibitors, finally, we proposed a therapeutic model based on an ING2 biomarker-guided strategy.
The objective of this paper is to synthesise current knowledge on ALK rearrangement and its impact on the management of advanced NSCLC. Several inhibitors of the tyrosine kinase of ALK (crizotinib, ceritinib, alectinib) have been approved as first line therapies in patients with advanced ALK positive NSCLC, which are associated with a better median progression-free survival than conventional chemotherapy. Unfortunately, the emergence of drug resistance leads to tumor progression. In patients with oligoprogressive disease if local ablative therapy can be effected, continuing with the same ALK tyrosine kinase inhibitor is on...
Publication date: Available online 15 November 2019Source: Biosensors and BioelectronicsAuthor(s): Liying Zhao, Huaixia Yang, Xiaoke Zheng, Jinge Li, Lihe Jian, Weisheng Feng, Jinming KongAbstractCytokeratin fragment antigen 21–1 (CYFRA 21–1) DNA is a crucial biomarker closely associated with non-small cell lung cancer. Here, we fabricated a novel electrochemical biosensor for ultrasensitive detection of CYFRA 21–1 DNA via polysaccharide and electrochemically mediated atom transfer radical polymerization (eATRP) dual signal amplification. Specifically, thiolated peptide nucleic acid (PNA) probes at 5&prim...
This study offers a great potential for ECL as an alternative safer radiosensitizer for increasing the RT efficiency against NSCLC. PMID: 31727206 [PubMed - as supplied by publisher]
Authors: Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW Abstract ROS1 gene fusions account for approximately 1-2% of all cases of non-small cell lung cancer (NSCLC). Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology. The ROS1 gene has homology to ALK and this structural similarity formed the basis for utilizing ALK inhibitors for ROS1+ NSCLC. On the basis of impressive progression-free survival of 19.2 months from the PROFILE 1001 trial, crizotinib obt...
Conclusion: Leptin produced by CAF promotes proliferation and migration of NSCLC cells probably via PI3K/AKT and MAPK/ERK1/2 signaling pathways in a paracrine manner. PMID: 31119158 [PubMed - indexed for MEDLINE]
Conditions: Detection; Segmentation Intervention: Other: Automatic detection and segmentation of NSCLC tumors Sponsors: Maastricht University; Hospital Center Universitaire De Liege, Liege, Belgium.; University Hospital RWTH Aachen University, Aachen, Germany.; Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang street, Dalian 116001, China; University of California San Francisco, San Franc isco, California, CA. Active, not recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Biological: MK-5890 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Biological: MK-4830 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Biological: MK-7684 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting